5:32 PM
 | 
Feb 25, 2013
 |  BC Extra  |  Clinical News

Dalbavancin meets endpoint in second Phase III ABSSI trial

Durata Therapeutics Inc. (NASDAQ:DRTX) said IV dalbavancin met the FDA-defined and EMA-defined primary endpoints of non-inferiority to twice-daily vancomycin in the 739-patient Phase III DISCOVER 2 trial to treat acute bacterial skin and skin structure infections (ABSSSI). The FDA-defined primary endpoint was non-inferiority to twice-daily vancomycin in the proportion of patients...

Read the full 237 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >